U.S. Markets closed

Merck overhang removed, says Wells Fargo

After regulators determined that a study of Merck's ezetimibe/simvastatin combination could continue following a review of interim data, Wells Fargo believes that the possibility of negative news from the review had been an overhang on the stock that has now been removed. The firm maintains an Outperform rating on the shares.